Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440463 | 0.95 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2SLC18A2 | |
| SCHEMBL18253935 | 0.93 | KDM4E (0.53) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL5593717 | 0.90 | KDM4E (0.56) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL31285559 | 0.89 | KDM4E (0.55) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL18253939 | 0.84 | KDM4E (0.56) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL31285728 | 0.83 | KDM4E (0.49) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29169546 | 0.82 | PTGS2 (0.57) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL4595 | 0.82 | PTGS2 (0.57) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL9790769 | 0.82 | PTGS2 (0.57) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL7338783 | 0.81 | PTGS2 (0.56) | KDM4ENPC1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-1735286-B1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| EP-1735286-B1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| WO-2007072089-A1 | MGLUR5 ANTAGONISTIC CARBAMOYL-OXIME DERIVATIVES | RICHTER GEDEON VEGYÉSZETU GYÁR RT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1735286-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-27 | — | — | EP | disclosed |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005095353-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | WO | disclosed |
| US-4187152-A | Extractive distillation for separating ketones and/or alcohols from phenol and/or cresol | ALLIED CHEMICAL CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | CNR2, CNR1, GPR18 | KDM4E 1714/4885NPC1 252/4885RAB9A 1166/4885 |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | KDM4E 1714/4885NPC1 252/4885RAB9A 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.